<DOC>
	<DOCNO>NCT01729091</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose immune cell call natural killer ( NK ) cell give chemotherapy stem cell transplant patient myeloma . Researchers want learn add NK cell help make stem cell transplant effective treating disease . The safety treatment also study . NK cell may kill myeloma cell remain body last chemotherapy treatment . The NK cell separate umbilical cord blood sample . These separate NK cell `` grow '' ( manipulate ) lab increase number NK cell give vein . Lenalidomide ( Revlimid ) design block protein play role cell function growth , may cause cancer cell die . Melphalan design attach DNA ( genetic material ) cell , may cause cancer cell die . It commonly use stem cell transplantation .</brief_summary>
	<brief_title>Study Umbilical Cord Blood-derived Natural Killer Cells Conjunction With High Dose Chemotherapy Autologous Stem Cell Transplant Patients With Multiple Myeloma</brief_title>
	<detailed_description>NK Cell Dose Levels : If choose participate study , assign dose level NK cell base join study . Up 4 dose level NK cell test . Three ( 3 ) participant enrol dose level high tolerable dose level find . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose NK cell find . When high tolerable dose find , participant may enrol dose level . Chemotherapy , NK Autologous Cell Infusions : In stem cell transplant , day receive stem cell call minus day . The day receive stem cell call Day 0 . The day receive stem cell call plus day . On Day -8 , admit hospital receive hydration fluid vein . On Days -8 -2 , take lenalidomide mouth 1 time day . You swallow lenalidomide capsule whole water time day . Do break , chew , open capsule . If miss dose lenalidomide , take soon remember day . If miss take dose entire day , take regular dose next schedule day . Do take double regular dose make miss dose . If take prescribe dose lenalidomide seek emergency medical care need contact study staff right away . On Day -7 , receive melphalan vein 30 minute . On Day -5 ( +/-1 day ) , receive NK cell vein 1 hour . On Day 0 , receive stem cell transplant vein 30-60 minute . Starting Day 0 , receive filgrastim ( G-CSF ) needle skin 1 time day every day white blood cell count begin recover . Filgrastim design help cell bone marrow multiply , help raise white blood cell count quickly , low fever , decrease risk infection . You receive antibiotic standard care help prevent infection . You may receive lenalidomide , melphalan , NK cell , and/or transplant outpatient , study doctor approves . Pregnancy Tests While Taking Lenalidomide : Women able become pregnant must 3 negative pregnancy test : within 10-14 day lenalidomide prescribe , within 24 hour lenalidomide prescribe , 28 day last lenalidomide dose . You must fill prescription within 7 day . One ( 1 ) time week first month start take lenalidomide , woman able become pregnant blood ( 1 teaspoon ) drawn pregnancy test . Then , female regular menstrual cycle , blood ( 1 teaspoon ) drawn pregnancy test 28 day last dose lenalidomide . If menstrual cycle irregular , blood ( 1 teaspoon ) drawn every 2 week , around 14 28 day last dose lenalidomide . These blood test part routine blood draw whenever possible . Study Visits : Before start treatment , follow tests/procedures perform do part routine pre-transplant procedure : - You bone marrow aspiration biopsy check status disease . To collect bone marrow aspiration , area hip chest bone numb anesthetic , small amount bone bone marrow withdrawn large needle . - You series x-ray ( bone survey ) check status disease . - Blood ( 2 tablespoon ) urine collect check status disease . - You ask symptom may . Up twice week Day -4 Day +7 , blood ( 2 tablespoon time ) drawn check donor NK cell , one first 12 participant enrol study . If donor NK cell find , blood ( 2 tablespoon time ) draw 1 time week around Day +30 ( +/-3 day ) . From 30 100 day stem cell transplant , blood drawn NK cell blood last blood draw routine follow-up visit . At visit NK cell infusion Day -5 , often study doctor think need , check possible reaction transplant study drug , include graft versus host disease ( GVHD ) . GVHD condition transplant tissue attack body transplant patient receive stem cell transplant . Graft failure occur transplanted stem cell may able grow multiply body . If happens , high risk infection and/or bleed . If number white blood cell get back high enough level within 3 week transplant , stem cell may need give . Blood ( 2 teaspoon ) draw urine collect routine test check kidney liver function often study doctor think need . Long-Term Follow-Up : About 30 day stem cell transplant : - Blood ( 4 tablespoon ) draw check status disease . - Urine collect check status disease . - If study doctor think need , bone marrow aspiration biopsy check status disease . About 100 day stem cell transplant , blood ( 4 tablespoon ) draw urine collect check status disease . If study doctor think need , bone marrow aspiration biopsy check status disease . Length Study : You remain study 100 day stem cell transplant . Your participation study complete long-term follow-up visit . You take study early disease get bad , infection , intolerable side effect occur , able receive stem cell transplant , need medical treatment allow study , study doctor decide best interest , keep appointment take study drug instruct , decide want leave study early . This investigational study . The way researcher make NK cell investigational . At time , use research . Lenalidomide FDA approve commercially available treat patient multiple myeloma receive least 1 prior therapy . Melphalan commercially available FDA approve treatment myeloma . Up 60 participant enrol study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Patients multiple myeloma transplant candidate . 2 . 18 75 year age . 3 . Performance score least 70 % Karnofsky 0 2 ECOG . 4 . Adequate major organ system function demonstrate : . Left ventricular ejection fraction great 40 % . b . Pulmonary function test ( PFT ) demonstrate diffusion capacity least 40 % predict . c. Estimated serum creatinine clearance &gt; /=60 ml/min ( use CockcroftGault formula : creatinine clearance = [ ( 140age ) *kg/ ( 72*serum creatinine ) ] * 0.85 female ) and/or serum creatinine &lt; /=1.6 mg/dL . d. SGPT le 3 x upper limit normal . e. Total bilirubin le 2 x upper limit normal . 5 . All study participant must register mandatory Revlimid REMS program , willing able comply requirement Revlimid REMS program . 6 . Females reproductive potential must adhere scheduled pregnancy test require Revlimid REMS program . 7 . Men must agree use latex condom sexual contact female child bear potential even successful vasectomy . 8 . Patients must CB unit available match patient 4 , 5 , 6/6 HLA class I ( serological ) II ( molecular ) antigens . 9 . Availability autologous peripheral blood stem cell graft , contain least 6.0 x 10^6 CD34+ cells/kg . 10 . Patient legally authorize representative able sign inform consent . 1 . Patients receive investigational agent . 2 . History allergic reaction attribute compound similar chemical biologic composition melphalan . 3 . Known hypersensitivity desquamate rash either thalidomide lenalidomide . 4 . Uncontrolled intercurrent illness include , limited ongoing active infection , uncontrolled hypertension ( systolic &gt; 160 , diastolic &gt; 100 despite antihypertensive therapy , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 5 . HIVpositive patient exclude due increase risk lethal infection treat myeloablative chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>MM</keyword>
	<keyword>Umbilical cord blood</keyword>
	<keyword>UCB</keyword>
	<keyword>Natural killer cell</keyword>
	<keyword>NK</keyword>
	<keyword>Autologous stem cell transplant</keyword>
	<keyword>Stem cell infusion</keyword>
	<keyword>High dose chemotherapy</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>IL-2</keyword>
	<keyword>Aldesleukin</keyword>
	<keyword>Proleukin</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
</DOC>